US 11,926,651 B2
Polypeptide construct comprising fragments of allergens
Monika Hochradl, Vienna (AT); Frank Stolz, Vienna (AT); Angela Neubauer, Vienna (AT); Rainer Henning, Vienna (AT); and Elijahu Babaev, Vienna (AT)
Assigned to WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD., Huzhou (CN)
Appl. No. 16/335,022
Filed by WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD., Huzhou (CN)
PCT Filed Sep. 20, 2017, PCT No. PCT/EP2017/073808
§ 371(c)(1), (2) Date Mar. 20, 2019,
PCT Pub. No. WO2018/054993, PCT Pub. Date Mar. 29, 2018.
Claims priority of application No. 16189774 (EP), filed on Sep. 20, 2016.
Prior Publication US 2019/0248844 A1, Aug. 15, 2019
Int. Cl. C07K 14/415 (2006.01); A61K 39/00 (2006.01); A61K 39/36 (2006.01); A61P 37/08 (2006.01); C07K 14/005 (2006.01); C12N 5/10 (2006.01); C12N 15/00 (2006.01); C12N 15/64 (2006.01); C12N 15/66 (2006.01)
CPC C07K 14/415 (2013.01) [A61K 39/36 (2013.01); A61P 37/08 (2018.01); C07K 14/005 (2013.01); C12N 5/10 (2013.01); C12N 15/00 (2013.01); C12N 15/64 (2013.01); C12N 15/66 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6075 (2013.01); C07K 2319/00 (2013.01); C07K 2319/21 (2013.01); C12N 2511/00 (2013.01); C12N 2523/00 (2013.01); C12N 2730/10122 (2013.01); C12N 2730/10134 (2013.01)] 23 Claims
 
1. A polypeptide construct comprising at least a first and a second fragment of a mature allergen derived from an allergen of the Amb a 1 family of Ambrosia artemisiifolia, wherein the first and second fragments are not located adjacent to each other in the mature allergen, wherein each of the first and second fragments consists of up to 50 amino acid residues, wherein
a. the first fragment is derived from the N-terminus of the mature allergen, wherein:
the first fragment comprises a sequence selected from the group consisting of AEDLQEILPVNETRRLTTSGAYNIIDGX1(SEQ ID No. 2); AEDLQQILPSANETRSLTTX2GTYNIIDGX1 (SEQ ID No. 3); AEGVGEILPSVNETRSLQAX2EAYNIIDKX1 (SEQ ID No. 4); and AEDVEEFLPSANETRRSLKAX2EAHNIIDKX1 (SEQ ID No. 5);
wherein X1 is cysteine, serine or no amino acid residue and X2 is cysteine or serine, and
b. the second fragment is derived from the C-terminus of the mature allergen, wherein:
the second fragment comprises a sequence selected from the group consisting of
X3RX4GFX5QVVNNNYX6X7WGX8YAX9GGSX10X11PTIL (SEQ ID No. 6);
X12DPVLTPX13QX14AGMIPAEPGEX15X16X17X18LTSSAGVLS X19 (SEQ ID No. 7);
X20RHGFFQVVNNNYDKWGSYAIGGSASPTIL (SEQ ID No. 8); X21RFGFFQVVNNNYDRWGTYAIGGSSAPTIL (SEQ ID No. 9); VDPVLTPEQSAGMIPAEPGESALSLTSSAGVLSX22 (SEQ ID No. 10); and
SDPVLTPVQSAGMIPAEPGEAAIKLTSSAGVLSX23 (SEQ ID No. 11),
wherein X3 is cysteine, serine, leucine or no amino acid residue, X4 is histidine or phenylalanine, X5 is phenylalanine or valine, X6 is aspartic acid or glutamic acid, X7 is arginine or lysine, X8 is threonine or serine, X9 is isoleucine or leucine, X10 is serine or alanine and X11 is glycine, serine or alanine, X12 is serine or valine, X13 is valine or glutamic acid, X14 is serine, lysine or asparagine, X15 is alanine or serine, X16 is valine or alanine, X17 is leucine or isoleucine, X18 is serine, lysine or arginine and X19 is cysteine, serine or no amino acid residue, X20 and X21 are independently cysteine, leucine, serine or no amino acid residue, X22 and X23 are independently cysteine, serine or no amino acid residue,
wherein the first and second fragments are fused or conjugated to a carrier protein, wherein at least one of the first or second fragments is fused to the N-terminus of the carrier protein and at least one of the first or second fragments is fused to the C-terminus of the carrier protein.